Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
DMAC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.14 - $6.82
Previous CloseN/A
Volume70.76K
Average Volume (3M)92.09K
Market Cap
$149.99M
Enterprise Value$129.30M
Total Cash (Recent Filing)$337.90K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 20, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding42,855,660
10 Day Avg. Volume120,962
30 Day Avg. Volume92,091
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.85
Forecast
1Y Price Target
$10.50Price Target Upside210.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Diamedica Therapeutics News
PremiumCompany Announcements
DiaMedica Therapeutics Reports 2024 Financial Results
PremiumCompany Announcements
DiaMedica Therapeutics’ Optimistic Earnings Call Highlights
PremiumCompany Announcements
DiaMedica Therapeutics Appoints Daniel J. O’Connor to Board---
Bulls Say, Bears Say
Bulls Say
Market PotentialSignificant market share potential exists for DM199 in preeclampsia and acute ischemic stroke, given the limited current treatment options.
Potential AcquisitionPositive preeclampsia results could solidify the company as a likely takeout candidate, potentially catalyzed by positive stroke data.
Regulatory AdvantagesThe application for Orphan Drug Designation for early-onset preeclampsia could provide additional regulatory and financial advantages for DiaMedica.
Bears Say
Enrollment ChallengesThe ongoing Phase 2/3 ReMEDy2 trial of DM199 in acute ischemic stroke patients has refined its study protocol to incorporate thrombolytic non-responders to expand the eligible patient pool and facilitate enrollment.
Study DelaysThe delay in the ReMEDy2 interim analysis readout is not an ideal message.
---
Ownership Overview
33.79% Insiders
3.83% Mutual Funds
― Other Institutional Investors
59.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $2.14 and its highest was $6.82 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $149.99M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is May 20, 2025 which is in 41 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Mar 17, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.172 by -$0.008.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 42,855,660 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.172. Following the earnings report the stock price went down -13.022%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
---
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (210.65% Upside)
$10.50 (210.65% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.77%
12-Months-Change
Fundamentals
Return on Equity
-53.27%
Trailing 12-Months
Asset Growth
-14.43%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
---
DMAC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the preeclampsia and stroke programs, particularly with the expansion of clinical sites and positive safety reviews. However, challenges such as delayed enrollment in the stroke program and increased R&D expenses were noted. Despite these challenges, the overall sentiment leans towards optimism due to the advancements and financial stability.Read More>---
DMAC Stock 12 Month Forecast
Average Price Target
$10.50
▲(210.65% Upside)
Technical Analysis
Best Analysts Covering DMAC
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
-7.07%
reiterated a buy rating 23 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -7.07% per trade.
---